Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 3
1976 12
1977 7
1978 12
1979 23
1980 17
1981 14
1982 32
1983 27
1984 5
1985 22
1986 15
1987 26
1988 25
1989 37
1990 34
1991 26
1992 17
1993 12
1994 5
1995 9
1996 1
1997 4
1998 4
1999 3
2000 3
2001 4
2002 2
2003 5
2004 1
2005 2
2006 5
2007 6
2008 5
2009 2
2010 3
2011 7
2012 7
2013 6
2014 6
2015 5
2016 7
2017 3
2018 5
2019 8
2020 8
2022 5
2023 4
2024 4
2025 3
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

491 results

Results by year

Filters applied: . Clear all
Page 1
Effectiveness of nifedipine, labetalol, and hydralazine as emergency antihypertension in severe preeclampsia: a randomized control trial.
S D, Novri DA, Hamidy Y, Savira M. S D, et al. F1000Res. 2023 Apr 27;11:1287. doi: 10.12688/f1000research.125944.2. eCollection 2022. F1000Res. 2023. PMID: 37273965 Free PMC article. Clinical Trial.
A single dose administration, four, one, and three patients had 20% MAP reduction in nifedipine, labetalol, and hydralazine group. Three, seven, and one patient had a failure of reaching 20% MAP reduction even after receiving the third dose. The effectiveness of the drugs …
A single dose administration, four, one, and three patients had 20% MAP reduction in nifedipine, labetalol, and hydralazine group. Th …
Pregnancy Outcomes of Nifedipine Compared With Labetalol for Oral Treatment of Mild Chronic Hypertension.
Sanusi AA, Leach J, Boggess K, Dugoff L, Sibai B, Lawrence K, Hughes BL, Bell J, Aagaard K, Edwards RK, Gibson KS, Haas DM, Plante L, Metz TD, Casey B, Esplin S, Longo S, Hoffman MK, Saade GR, Hoppe KK, Foroutan J, Tuuli M, Owens MY, Simhan HN, Frey H, Rosen T, Palatnik A, Baker S, August P, Reddy UM, Su EJ, Krishna I, Nguyen NA, Norton ME, Skupski D, El-Sayed YY, Ogunyemi D, Galis ZS, Harper L, Ambalavanan N, Geller NL, Kuo HC, Sinkey RG, Librizzi R, Pereira L, Magann EF, Habli M, Williams S, Mari G, Pridjian G, McKenna DS, Parrish M, Eugene Chang, Osmundson S, Quinones J, Szychowski JM, Tita ATN. Sanusi AA, et al. Obstet Gynecol. 2024 Jul 1;144(1):126-134. doi: 10.1097/AOG.0000000000005613. Epub 2024 May 23. Obstet Gynecol. 2024. PMID: 38949541 Free PMC article. Clinical Trial.
We performed three comparisons based on medications prescribed at enrollment: labetalol compared with standard care, nifedipine compared with standard care, and labetalol compared with nifedipine. ...The primary outcome occurred in 217 (30.1%), 130 (31.2%), and 427 …
We performed three comparisons based on medications prescribed at enrollment: labetalol compared with standard care, nifedipine compa …
Oral antihypertensive regimens (nifedipine retard, labetalol, and methyldopa) for management of severe hypertension in pregnancy: an open-label, randomised controlled trial.
Easterling T, Mundle S, Bracken H, Parvekar S, Mool S, Magee LA, von Dadelszen P, Shochet T, Winikoff B. Easterling T, et al. Lancet. 2019 Sep 21;394(10203):1011-1021. doi: 10.1016/S0140-6736(19)31282-6. Epub 2019 Aug 1. Lancet. 2019. PMID: 31378394 Free PMC article. Clinical Trial.
However, the primary outcome did not differ between the nifedipine and labetalol groups (249 [84%] women vs 228 [77%] women; p=0.05) or the labetalol and methyldopa groups (p=0.80). ...As single drugs, nifedipine retard use resulted in a greater frequency of primary …
However, the primary outcome did not differ between the nifedipine and labetalol groups (249 [84%] women vs 228 [77%] women; p=0.05) …
Optimal treatment for women with acute hypertension in pregnancy; a randomized trial comparing intravenous labetalol versus nicardipine.
Bij de Weg JM, de Boer MA, Gravesteijn BY, Hermes W, Ganzevoort W, van Bel F, Willem Mol B, de Groot CJM. Bij de Weg JM, et al. Pregnancy Hypertens. 2024 Dec;38:101153. doi: 10.1016/j.preghy.2024.101153. Epub 2024 Sep 1. Pregnancy Hypertens. 2024. PMID: 39222572 Free article. Clinical Trial.
In absence of evidence, guidelines recommend either intravenous labetalol or nicardipine. We compared the effectiveness and safety of these two drugs in women with severe hypertension in pregnancy. ...Respiratory distress syndrome occurred more often in the labetalol …
In absence of evidence, guidelines recommend either intravenous labetalol or nicardipine. We compared the effectiveness and safety of …
Comparison of labetalol and lidocaine in induction of controlled hypotension in tympanoplasty: a randomized clinical trial.
Karami A, Fattahi Saravi Z, Hosseini H, Rahmati M, Jahangiri R, Asmarian N, Banifatemi M. Karami A, et al. Braz J Otorhinolaryngol. 2024 May-Jun;90(3):101403. doi: 10.1016/j.bjorl.2024.101403. Epub 2024 Feb 22. Braz J Otorhinolaryngol. 2024. PMID: 38442640 Free PMC article. Clinical Trial.
Patients were randomly assigned to receive either 0.5-2 mg/min labetalol or 1.5 mg/kg/h lidocaine 1% to achieve controlled hypotension during surgery. ...RESULTS: The hemodynamic parameters showed a similar trend over time in both the labetalol and lidocaine groups. …
Patients were randomly assigned to receive either 0.5-2 mg/min labetalol or 1.5 mg/kg/h lidocaine 1% to achieve controlled hypotensio …
Association Between Intravenous Antihypertensives and Functional Outcome After Successful Endovascular Thrombectomy.
Jung JW, Kim YD, Heo J, Lee H, Kim BM, Kim DJ, Shin NY, Joo H, Cho BH, Ahn SH, Park H, Sohn SI, Hong JH, Yun J, Song TJ, Chang Y, Kim GS, Seo KD, Lee K, Chang JY, Seo JH, Lee S, Baek JH, Cho HJ, Shin DH, Kim J, Yoo J, Baik M, Jung YH, Hwang YH, Kim CK, Kim JG, Lee IH, Choi JK, Lee CJ, Park S, Jeon S, Lee HS, Kim KH, Kwon SU, Bang OY, Heo JH, Nam HS; OPTIMAL-BP Trial Investigators. Jung JW, et al. Stroke. 2025 Sep;56(9):2503-2515. doi: 10.1161/STROKEAHA.125.051696. Epub 2025 Jul 3. Stroke. 2025. PMID: 40605757 Free article. Clinical Trial.
Among the 141 patients who received intravenous antihypertensives, 133 (94.3%) were treated with nicardipine, 10 (7.0%) received labetalol, and 2 (1.4%) were administered both drugs. Patients who received intravenous antihypertensives had significantly lower rates of funct …
Among the 141 patients who received intravenous antihypertensives, 133 (94.3%) were treated with nicardipine, 10 (7.0%) received labetalo …
Comparison of intravenous labetalol and hydralazine for severe hypertension in pregnancy in Northeastern Nigeria: A randomized controlled trial.
Muhammad S, Usman H, Dawha YM, Yahya A, Yekeen A, Bako B. Muhammad S, et al. Pregnancy Hypertens. 2022 Aug;29:1-6. doi: 10.1016/j.preghy.2022.05.001. Epub 2022 May 8. Pregnancy Hypertens. 2022. PMID: 35605426 Clinical Trial.
RESULTS: One hundred and thirteen patients' data were analyzed (fifty-six [56] in the hydralazine group and fifty-seven [57] in the labetalol group). There were no significant differences in the fall of the mean arterial blood pressure (labetalol; 24.19 mmHg/hydrala …
RESULTS: One hundred and thirteen patients' data were analyzed (fifty-six [56] in the hydralazine group and fifty-seven [57] in the labet …
Methyldopa versus labetalol or no medication for treatment of mild and moderate chronic hypertension during pregnancy: a randomized clinical trial.
Rezk M, Emarh M, Masood A, Dawood R, El-Shamy E, Gamal A, Badr H. Rezk M, et al. Hypertens Pregnancy. 2020 Nov;39(4):393-398. doi: 10.1080/10641955.2020.1791902. Epub 2020 Jul 22. Hypertens Pregnancy. 2020. Retraction in: Hypertens Pregnancy. 2023 Dec;42(1):2268991. doi: 10.1080/10641955.2023.2268991. PMID: 32697618 Free article. Retracted. Clinical Trial.
OBJECTIVE: to assess the maternal and fetal outcome in women with mild to moderate chronic hypertension on antihypertensive drug (methyldopa or labetalol) therapy compared to no medication. METHODS: This multicenter randomized clinical study was conducted at Menoufia Unive …
OBJECTIVE: to assess the maternal and fetal outcome in women with mild to moderate chronic hypertension on antihypertensive drug (methyldopa …
An Equivalence Trial Comparing Labetalol and Diltiazem in Controlling Emergence Hypertension after Supratentorial Tumor Surgery.
Sirivanasandha B, Sakaew A, Sutthivaiyakit K, Raksamani K, Waitayawinyu P, Rushatamukayanunt P, Punkla W. Sirivanasandha B, et al. J Med Assoc Thai. 2015 Nov;98(11):1104-11. J Med Assoc Thai. 2015. PMID: 26817181 Clinical Trial.
CONCLUSION: Labetalol has equivalent efficacy to diltiazem. Both drugs used low median dosage giving low incidence of side-effects. Labetalol is a good alternative drug to control hypertensive response during emergence from anesthesia for post-craniotomy....
CONCLUSION: Labetalol has equivalent efficacy to diltiazem. Both drugs used low median dosage giving low incidence of side-effects. …
Double-blind trial of labetalol.
Kane J, Gregg I, Richards DA. Kane J, et al. Br J Clin Pharmacol. 1976 Aug;3(4 Suppl 3):737-41. Br J Clin Pharmacol. 1976. PMID: 791329 Free article. Clinical Trial.
1 A new anti-hypertensive agent (labetalol) with alpha- and beta-adrenoreceptor-blocking properties has been assessed in 30 patients in a general practice. 2 Significant reduction in blood pressure and pulse rate occurred at a dose of 400 mg/d. ...
1 A new anti-hypertensive agent (labetalol) with alpha- and beta-adrenoreceptor-blocking properties has been assessed in 30 patients …
491 results